Eric Thomas Schmidt Allogene Therapeutics, Inc. (ALLO) insider trading activity

Eric Thomas Schmidt is Chief Financial Officer of Allogene Therapeutics, Inc.. Currently has a direct ownership of 862,439 shares of ALLO, which is worth approximately $2.21 Million. The most recent transaction as insider was on Mar 22, 2023, when has been sold 558,094 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 862K

0% 3M change

0% 12M change

Total Value Held $2.21 Million

ERIC THOMAS SCHMIDT Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 22 2023	BUY Grant, award, or other acquisition	-	558,094 Added 39.29%	862,439 Common Stock
Mar 14 2023	SELL Payment of exercise price or tax liability	$196,258 $5.47 p/Share	35,879 Reduced 10.55%	304,345 Common Stock
Mar 23 2022	BUY Grant, award, or other acquisition	-	237,358 Added 41.26%	337,904 Common Stock
Mar 15 2022	SELL Open market or private sale	$87,508 $7.63 p/Share	11,469 Reduced 10.24%	100,546 Common Stock
May 24 2021	BUY Exercise of conversion of derivative security	$271,423 $18.22 p/Share	14,897 Added 11.83%	110,994 Common Stock
Mar 26 2021	BUY Grant, award, or other acquisition	-	24,866 Added 20.56%	96,097 Common Stock
Mar 15 2021	SELL Open market or private sale	$307,866 $38.23 p/Share	8,053 Reduced 10.16%	71,231 Common Stock

Also insider at

RLMD

RELMADA THERAPEUTICS, INC. Healthcare

Director

RVMD

Revolution Medicines, Inc. Healthcare

ETS